Oncimmune Holdings PLC (GB:ONC)
LSE:ONC

Oncimmune Holdings (ONC) Income Statement

2 Followers

Oncimmune Holdings Income Statement

Last quarter (Q4 2022), Oncimmune Holdings's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Oncimmune Holdings's net income was £―. See Oncimmune Holdings’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Aug 23Aug 22May 22May 21May 20
Total Revenue
-£ 1.15M£ 3.79M£ 3.86M£ 3.72M£ 509.00K
Cost of Revenue
-£ 360.00K£ 1.96M£ 2.40M£ 865.00K£ 537.00K
Gross Profit
-£ 792.00K£ 1.83M£ 1.46M£ 2.86M£ -28.00K
Operating Expense
-£ 5.16M£ 12.28M£ 10.04M£ 8.31M£ 9.86M
Operating Income
-£ -4.37M£ -10.46M£ -8.59M£ -5.46M£ -9.88M
Net Non Operating Interest Income Expense
-£ -2.00M£ -1.51M£ -943.00K£ -951.00K£ -515.00K
Other Income Expense
-£ -318.00K£ -411.00K---
Pretax Income
-£ -5.93M£ -11.56M£ -9.53M£ -5.70M£ -9.78M
Tax Provision
-£ 223.00K£ -173.00K£ -17.00K£ -1.07M£ -1.32M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ 4.10M£ -11.39M£ -9.51M£ -4.63M£ -8.46M
Basic EPS
-£ 0.06£ -0.16£ -0.14£ -0.07£ -0.13
Diluted EPS
-£ 0.06£ -0.16£ -0.14£ -0.07£ -0.13
Basic Average Shares
-£ 72.57M£ 69.03M£ 69.43M£ 64.57M£ 63.30M
Diluted Average Shares
-£ 72.57M£ 69.03M£ 69.43M£ 64.57M£ 63.30M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ 5.52M£ 14.25M£ 12.45M£ 9.18M£ 10.39M
Net Income From Continuing And Discontinued Operation
-£ 4.10M£ -11.39M£ -9.51M£ -4.63M£ -8.46M
Normalized Income
-£ -4.45M£ -11.73M£ -9.51M£ -4.88M£ -8.99M
Interest Expense
---£ 943.00K£ 837.00K£ 314.00K
EBIT
-£ -5.41M£ -10.48M£ -8.59M£ -4.86M£ -9.47M
EBITDA
-£ -4.43M£ -8.84M£ -7.16M£ -4.12M£ -8.97M
Currency in GBP

Oncimmune Holdings Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis